Third-generation versus first-generation EGFR tyrosine kinase inhibitors in Asian patients with advanced EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Third-generation EGFR-TKIs (TGETs) have demonstrated improved clinical outcomes compared to first-generation EGFR-TKIs (FGETs) in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Nonetheless, the comparative safety and efficacy of TGETs as a first-line option for Asian patients with advanced EGFR-mutant NSCLC remain unclear. This meta-analysis aims to compare the survival outcomes, response rates, and adverse events (AEs) of TGETs versus FGETs in this population.

Methods

We systematically searched 6 databases for eligible phase 3 randomized controlled trials (RCTs). Eligible studies included those comparing TGETs with FGETs in previously untreated Asian patients with EGFR-mutant advanced NSCLC. Pooled hazard ratios (HRs) for progression-free survival

SUBMITTER: Xu M 

PROVIDER: S-EPMC12540962 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature